- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03912545
Evaluation of the Clinical Performance of the Quantra System With the QStat Cartridge
Evaluation of the Clinical Performance of the Quantra System With the QStat Cartridge in Trauma and Obstetric Hemorrhage
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Quantra System is a fully integrated and automated in vitro diagnostic device which uses SEER Sonorheometry, an ultrasound-based technology, to characterize the viscoelastic properties of a whole blood sample during coagulation. The QStat Cartridge was developed to monitor hemostasis in patients that may experience a range of coagulopathies of various etiologies including fibrinolytic defects. These patients include the trauma and obstetric hemorrhage populations. The cartridge consists of four independent channels each containing different sets of reagents, which provide four measurements performed in parallel yielding five parameters that depict the functional status of a patient's coagulation system.
This single-center, prospective, observational pilot study will evaluate the performance of the Quantra System with the QStat Cartridge as compared to standard coagulation tests and comparable measures using conventional viscoelastic testing methods.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Texas
-
El Paso, Texas, United States, 79905
- Texas Tech University Health Sciences Center El Paso
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject is ≥ 18 years of age
Subject has one of the following conditions and is a candidate for a ROTEM test to be performed to access coagulopathy: trauma patient; patient with OB hemorrhage.
- For trauma patients; subject must be experiencing major trauma (preferably requiring the highest level of team activation) with active bleeding or deemed at high risk of significant bleeding according to mechanism of injury.
For subjects experiencing OB hemorrhage, one of the following conditions must be met (to be confirmed):
- Estimated blood loss during vaginal delivery is greater than 1000 mL
- Estimated blood loss during cesarean delivery is greater than 1500 mL
- Placental abruption with hemorrhage of any quantity blood loss
- Clinically suspected disseminated intravascular coagulation (DIC)
- Is under consideration for administration of tranexamic acid (TXA) for treatment of hemorrhage.
- Subject is willing to participate, and is willing to consent (either prospectively or by deferred consent)
Exclusion Criteria:
- Subject is younger than 18 years of age
- Subject is known to have received antifibrinolytic therapy immediately prior to presentation to trauma unit or during labor just prior to OB hemorrhage.
- Subject is unable to provide written informed consent (either prior to performing any study related procedures or by deferred consent)
- Subject is currently enrolled in a distinct study that might confound the results of the proposed study
- Subject is affected by a condition that, in the opinion of the clinical team, may pose additional risks.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Trauma patients
Subjects experiencing major trauma such that viscoelastic testing is performed as standard of care to assess coagulopathy.
|
Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Other Names:
|
Obstetric hemorrhage patients
Subjects experiencing obstetric hemorrhage such that viscoelastic testing is performed as standard of care is performed to assess coagulopathy.
|
Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of Quantra Clot Time and Clot Stiffness results to standard coagulation test results
Time Frame: Upon arrival to emergency department (trauma subjects) or upon presentation with obstetric hemorrhage, prior to the administration of blood products or antifibrinolytics in parallel with samples collected for routine ROTEM analysis and laboratory assays
|
Coagulation function assessed by Quantra and standard coagulation tests
|
Upon arrival to emergency department (trauma subjects) or upon presentation with obstetric hemorrhage, prior to the administration of blood products or antifibrinolytics in parallel with samples collected for routine ROTEM analysis and laboratory assays
|
Comparison of Quantra Clot Time and Clot Stiffness results to ROTEM Delta results
Time Frame: Upon arrival to emergency department (trauma subjects) or upon presentation with OB hemorrhage, prior to the administration of blood products or antifibrinolytics in parallel with samples collected for routine ROTEM analysis and laboratory assays
|
Coagulation function assessed by Quantra and ROTEM Delta
|
Upon arrival to emergency department (trauma subjects) or upon presentation with OB hemorrhage, prior to the administration of blood products or antifibrinolytics in parallel with samples collected for routine ROTEM analysis and laboratory assays
|
Comparison of Quantra Fibrinolysis results to ROTEM Delta results
Time Frame: Upon arrival to emergency department (trauma subjects) or upon presentation with OB hemorrhage, prior to the administration of blood products or antifibrinolytics in parallel with samples collected for routine ROTEM analysis and laboratory assays
|
Coagulation function assessed by Quantra and ROTEM Delta
|
Upon arrival to emergency department (trauma subjects) or upon presentation with OB hemorrhage, prior to the administration of blood products or antifibrinolytics in parallel with samples collected for routine ROTEM analysis and laboratory assays
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HEMCS-019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Trauma
-
Humacyte, Inc.Active, not recruitingTrauma | Trauma Injury | Trauma, Multiple | Trauma BluntUkraine
-
Prof. Dr. Cemil Tascıoglu Education and Research...CompletedTrauma Injury | Trauma, MultipleTurkey
-
Rabin Medical CenterIsraeli Ministry of SecurityUnknown
-
University Hospital, AngersRecruiting
-
Wonju Severance Christian HospitalNational Research Foundation of KoreaRecruitingTrauma Injury | Trauma, MultipleKorea, Republic of
-
Chang, Steve S., M.D.Santa Barbara Cottage Hospital; Accumetrics, Inc.CompletedHead Injury Trauma BluntUnited States
-
Oslo University HospitalUniversity of Oslo; Sunnaas Rehabilitation Hospital; South-Eastern Norway Regional...RecruitingTrauma Injury | Trauma, Multiple | PolytraumaNorway
-
Assistance Publique - Hôpitaux de ParisFrancophone Pediatric Resuscitation and Emergency Group (GFRUP)Completed
-
Fundacion Clinica Valle del LiliUniversity of Pittsburgh; Hospital Universitario del Valle Evaristo GarciaRecruitingTrauma | Trauma Injury | Trauma, MultipleColombia
Clinical Trials on Quantra System
-
HemoSonics LLCCompletedCoagulationUnited States
-
HemoSonics LLCCompletedBlood Loss, SurgicalUnited States
-
HemoSonics LLCCompletedTrauma | Blood Loss MassiveUnited States
-
HemoSonics LLCCompletedBlood Loss, SurgicalUnited States
-
HemoSonics LLCCompleted
-
HemoSonics LLCUniversity of California, IrvineCompletedThrombosis | Blood Loss | Extracorporeal Circulation; ComplicationsUnited States
-
HemoSonics LLCCompletedCoagulation Disorder | COVID | Disseminated Intravascular CoagulationUnited States
-
HemoSonics LLCCompleted